- Home
- BCLI vs BMRA Comparison
BCLI vs BMRA Comparison
Compare BCLI & BMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCLI
- BMRA
- Stock Information
- Founded
- BCLI 2000
- BMRA 1971
- Country
- BCLI United States
- BMRA United States
- Employees
- BCLI N/A
- BMRA N/A
- Industry
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- BMRA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- BCLI Health Care
- BMRA Health Care
- Exchange
- BCLI Nasdaq
- BMRA Nasdaq
- Market Cap
- BCLI 6.4M
- BMRA 7.4M
- IPO Year
- BCLI N/A
- BMRA N/A
- Fundamental
- Price
- BCLI $1.21
- BMRA $0.33
- Analyst Decision
- BCLI Strong Buy
- BMRA
- Analyst Count
- BCLI 1
- BMRA 0
- Target Price
- BCLI $30.00
- BMRA N/A
- AVG Volume (30 Days)
- BCLI 118.2K
- BMRA 337.1K
- Earning Date
- BCLI 11-14-2024
- BMRA 10-15-2024
- Dividend Yield
- BCLI N/A
- BMRA N/A
- EPS Growth
- BCLI N/A
- BMRA N/A
- EPS
- BCLI N/A
- BMRA N/A
- Revenue
- BCLI N/A
- BMRA $5,509,000.00
- Revenue This Year
- BCLI N/A
- BMRA N/A
- Revenue Next Year
- BCLI N/A
- BMRA N/A
- P/E Ratio
- BCLI N/A
- BMRA N/A
- Revenue Growth
- BCLI N/A
- BMRA 1.74
- 52 Week Low
- BCLI $1.05
- BMRA $0.24
- 52 Week High
- BCLI $11.85
- BMRA $2.13
- Technical
- Relative Strength Index (RSI)
- BCLI 23.69
- BMRA 45.05
- Support Level
- BCLI $1.05
- BMRA $0.34
- Resistance Level
- BCLI $1.95
- BMRA $0.44
- Average True Range (ATR)
- BCLI 0.20
- BMRA 0.04
- MACD
- BCLI -0.00
- BMRA -0.00
- Stochastic Oscillator
- BCLI 15.84
- BMRA 23.21
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
About BMRA Biomerica Inc.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. The majority of the company's revenue is earned from the Europe market.